Design and baseline characteristics for the ace inhibitor after anthracycline (aaa) study of cardiac dysfunction in long-term pediatric cancer survivors

American Heart Journal

Volumn 142, Issue 4, 2001, Pages 577-585

  Silber, Jeffrey H ^a   Cnaan, Avital ^a   Clark, Bernard J ^a   Paridon, Stephen M ^a   Chin, Alvin J ^a   Rychik, Jack ^a   Hogarty, Alexa N ^a   Cohen, Mitchell I ^a   Barber, Gerald ^c   Rutkowsky, Monica ^c   Kimball, Thomas R ^b   DeLaat, Cynthia ^b   Steinherz, Laurel J ^d   Zhao, Huaqing ^a   Tartaglione, Margaret R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ANGIONEUROTIC EDEMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG RESPONSE; EXERCISE; FEMALE; HEART DISEASE; HEART INDEX; HEART LEFT VENTRICLE WALL; HEART STRESS; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCREENING TEST; UNITED STATES; VERTIGO;

EID: 0034802466     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.118115     Document Type: Article

References (44)

1. The impact of childhood cancer on the United States and the world
2. Cardiac toxicity 4 to 20 years after completing anthracydine therapy
3. Risk factors for doxorubicin-induced congestive heart failure
4. Cardiotoxicity of adriamycin (NSC-123127) in children
5. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
6. Increased risk of cardiac dysfunction after anthracyclines in girls
7. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: A series of 15 patients
8. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
9. Long term cardiac follow-up 4-13 years after anthracycline therapy
10. Monitoring for anthracydine cardiotoxicity
11. Anthracydine-induced cardiotoxicity
12. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults
13. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group
14. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience
15. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart foilure
16. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
17. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
18. Captopril in infants for congestive heart failure secondary to a large ventricular left-to-right shunt
19. Captopril in heart failure secondary to a left to right shunt
20. Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy
21. The effect of treatment with angiotensim-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy
22. Beneficial effects of 1-year captopril therapy in children with chronic aortic regurgitation who have no symptoms
23. Is captopril useful in decreasing pleural drainage in children after modified Fontan operation?
24. Captopril pharmacokinetics, blood pressure response and plasma reninactivity in normotensive children with renal scarring
25. Afterload reduction therapy in long term survivors of childhood cancer treated with doxorubicin
26. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: Summary of results from the Medical Outcomes Study
27. Canadian-French, German UK versions of the Child Health Questionnaire: Methodology and preliminary item scaling results
28. Patient-based health status measurements in pediatric dialysis: Expanding the assessment of outcome
29. Developing a measure of health outcomes in survivors of childhood cancer: A review of the issues
30. Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use
31. Angiotensin converting enzyme inhibitors in pregnancy
32. Postmorketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995
33. Design and statistical issues of the modification of diet in renal disease trial: The Modification of Diet in Renal Disease Study Group
34. Sequential monitoring for comparison of changes in a response variable in clinical studies
35. Protocols for exercise testing
36. Exercise testing
37. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: A load-independent index of myocardial contractility
38. Developmental modulation of myocardial mechanics: Age- and growth-related alterations in afterload and contractility
39. Sinus node function following systematically staged Fontan
40. Recent advances in first-pass radionuclide angiography
41. Random effects models for longitudinal data
42. High incidence of obesity in young adults after treatment of acute lymphobLastic leukemia in childhood
43. Cardiopulmonary exercise testing in evaluation of the functional capacity of survivors of childhood cancer
44. The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients